In January 2009, Pfizer announced its acquisition of Wyeth in a cash and stock deal valued at $68 billion. This deal represented the first mega-acquisition since the world economic crisis, which commenced in September 2008.
Jeff Kindler knew that the last acquisition (Pharmacia in 2003) had not gone as planned. Was Pfizer prepared for the Wyeth acquisition? Would it create new ones or solve some of the urgent problems of Pfizer?
PUBLICATION DATE: February 17, 2011 PRODUCT #: 910M53-PDF-ENG
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
Related Case Solutions & Analyses:
Princessa Beauty Products
Training and Development at RVA: A Nonprofit Organization
At Ford, Turnaround Is Job One
Premiere Distributing Inc.: The Popcorn Predicament
Mario Laborin and the Turnaround of Mexico’s Nacional Financiera (B)
Exit Strategy (A)
Trisha Wilson of Wilson & Associates, Spanish Version
BET.com
Gillette Co. (A): Pressure for Change
Redesigning Work in an Era of Cognitive Technologies
